ADMA Biologics, Inc. (ADMA) Q1 2021 Earnings Results

ADMA Biologics Misses on EPS, Stock Down 3.47%

ADMA Biologics reported a loss per share that was slightly better than expected, but the lack of revenue details and guidance contributed to a negative stock reaction. The stock fell by 3.47%, reflecting investor concerns about the company's current challenges and future outlook. Without clear guidance, investors may remain cautious in their approach to the stock.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.16	N/A	+4.19%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Overall, management expressed caution regarding market conditions. They acknowledged the difficulties faced but did not provide specific guidance.

Management highlighted ongoing challenges in the current market environment.

They emphasized the need for strategic adjustments moving forward.

ADMA Biologics Misses on EPS, Stock Down 3.47%

Key numbers

Management commentary

ADMA Biologics, Inc.

More earnings this week

ADMA Biologics Misses on EPS, Stock Down 3.47%

Key numbers

Management commentary